Abstract
In this issue of Cancer Discovery, AI-Ahmadie and colleagues identify a somatic mutation in the RAD50 gene as a likely contributing factor to an unusual curative response to systemic combination therapy employing the DNA-damaging agent irinotecan and a checkpoint kinase 1 inhibitor in a patient with recurrent, metastatic small-cell cancer. This study highlights the importance of in-depth analysis of exceptional responders to chemotherapy and targeted therapy in early-phase clinical trials and opens new avenues for developing cancer genome-based combination therapy to improve the efficacy of traditional chemotherapy through synthetically lethal interactions.
Original language | English (US) |
---|---|
Pages (from-to) | 988-990 |
Number of pages | 3 |
Journal | Cancer discovery |
Volume | 4 |
Issue number | 9 |
DOIs | |
State | Published - Sep 2014 |
Externally published | Yes |
ASJC Scopus subject areas
- Oncology